Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 12/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 12/20 | 0.34 |
| ▸ | RRM1 | P23921 | 12/20 | 0.34 |
| ▸ | RRM2B | Q7LG56 | 12/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12599606 | 0.85 | ACHE (0.31) | ACHE | |
| SCHEMBL19682446 | 0.82 | CHRM2 (0.33) | CHRM2CHRM1RRM1RRM2BACHE | |
| SCHEMBL20872550 | 0.82 | CHRM2 (0.34) | CHRM2CHRM1RRM1RRM2BACHE | |
| SCHEMBL29628524 | 0.82 | CHRM2 (0.33) | CHRM2CHRM1RRM1RRM2BACHE | |
| SCHEMBL29628526 | 0.82 | CHRM2 (0.33) | CHRM2CHRM1RRM1RRM2BACHE | |
| SCHEMBL29628557 | 0.82 | CHRM2 (0.34) | CHRM2CHRM1RRM1RRM2BACHE | |
| SCHEMBL22222494 | 0.81 | ACHE (0.33) | ACHELMNATRPA1PTGS1CACNA1C | |
| SCHEMBL9945905 | 0.81 | ACHE (0.33) | ACHELMNATRPA1PTGS1CACNA1C | |
| SCHEMBL10547149 | 0.79 | LMNA (0.37) | LMNATRPA1PTGS1CACNA1C | |
| SCHEMBL22014779 | 0.79 | LMNA (0.34) | CHRM1LMNATRPA1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322789-A1 | PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | BROADENBIO CO., LTD. (CN) | 2023-10-12 | — | — | US | disclosed |
| US-20200171028-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS HOLDINGS, LLC | 2020-06-04 | — | — | US | disclosed |
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149693-A1 | THERAPEUTIC COMPOUNDS | HTR2C, GRK2, GRK3 | CHRM2 1504/4885CHRM1 2187/4885RRM1 4316/4885 |
| US-20200171028-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC1, HDAC2 | CHRM2 4537/4885CHRM1 4570/4885RRM1 2372/4885 |
| US-20230322789-A1 | PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | PDXK, CMPK1, GCK | CHRM2 2459/4885CHRM1 2119/4885RRM1 3738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.